Invasive Mechanical Ventilation
Conditions
Keywords
Fospropofol, Propofol, Invasive mechanical ventilation, sedation
Brief summary
The goal of this clinical trial is to compare the safety and efficacy of fospropofol and propofol during sedation in invasively mechanically ventilated patients in the Anesthesia Intensive Care Unit (AICU). Specific objectives include the following: * Evaluate the sedative effects of fospropofol and propofol in invasively mechanically ventilated patients. Compare the sedative effects of the two medications using relevant clinical indicators and scoring tools, such as the Richmond Agitation-Sedation Scale (RASS). * Compare the safety of fospropofol and propofol during sedation. Monitor medication-related adverse reactions, such as respiratory depression, hypotension, arrhythmias, headache, injection site pain, and assess the differences in adverse reaction incidence between the two medications. * Compare the characteristics of recovery from sedation between PPD and propofol. Focus on the time from sedation to emergence from sedation and compare the differences in recovery time between the two medications. Participants will be sedated with fospropofol or propofol during invasive mechanical ventilation.
Interventions
DRUGFospropofol
Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
Sponsors
Henan Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-75 years old 2. Intubation and mechanical ventilation \<12h before enrollment 3. Expected to require continuous invasive ventilation and sedation less than 6h after admission to anesthesia intensive care unit (AICU). 4. Signed informed consent
Exclusion criteria
1. parturient, childbirth or lactating mothers 2. acute severe neurological disease or coma 3. chronic renal failure 4. previous mechanical ventilation \>12h 5. severe liver dysfunction (Child-Pugh score C) 6. BMI \>30kg/m2 (\>90kg) 7. dying
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The patient's Richmond Agitation-Sedation Scale (RASS) score and the incidence of adverse reactions | Admission to the intensive care unit to 2 hours after weaning off the ventilator. | The participant's RASS score was assessed by the caregiver and the occurrence of adverse reactions was recorded. Adverse effects include hypotension, bradycardia, tachycardia, agitation, pain at the injection site, nausea and vomiting, edema, fever, anemia, paresthesias, headache, and hypoxemia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse reactions during the follow-up period | 2 hours after weaning off the ventilator to 24 hours after leaving the intensive care unit. | Adverse effects include hypotension, bradycardia, tachycardia, agitation, pain at the injection site, nausea and vomiting, edema, fever, anemia, paresthesias, headache, and hypoxemia. |
| Extubation time | From admission to the intensive care unit to removal of the endotracheal tube | The time from admission to the intensive care unit to removal of the endotracheal tube |
Countries
China
Contacts
STUDY_CHAIRJiaqiang Q Zhang, M.D
Henan Provincial People's Hospital
Outcome results
None listed